Summary
A manifest presence of adenylate kinase activity in cerebrospinal fluid was found in patients with cerebral arteriosclerosis. This activity was significantly higher during treatment with co-dergocrine (Hydergin®) compared with the two periods before and after treatment.
Similar content being viewed by others
References
G. Ronquist and G. Firthz, Eur. Neurol.18, 106 (1979).
P. O. Alm, G. Frithz and G. Ronquist, Acta psychiat. scand59, 517 (1979).
I. Jonsson, H. Breim and G. Ronquist, Scand. J. infect. Dis.11, 11 (1979).
A. Terent, G. Ronquist, K. Bergström, R. Hällgren and H. Åberg, Stroke, in press (1981).
A. Schaefer, G. Unyi and A. K. Pfeifer, Biochem. Pharmac.21, 2289 (1972).
J. S. Meyer, S. Okamoto, K. Shimazu, A. Koto, T. Ohuchi, A. Sari and A. D. Ericsson, Stroke5, 180 (1974).
M. Huang and J. W. Daly, J. med. Chem.15, 458 (1972).
A. Chappuis, A. Enz and P. Zwangoff, Triangle14, 93 (1975).
Author information
Authors and Affiliations
Additional information
Acknowledgment. We are obliged to Mrs M. Hedström, for skilful technical assistance. This study was supported by a grant from the Södermanland Country Council. The study plan was approved by the Ethical Committy of Medical Faculty at the University of Uppsala.
Rights and permissions
About this article
Cite this article
Frithz, G., Ronquist, G. & Andersson, B. Drug action on adenylate kinase activity in cerebrospinal fluid of arteriosclerotic patients. Experientia 36, 1409–1410 (1980). https://doi.org/10.1007/BF01960129
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01960129